<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00487630</url>
  </required_header>
  <id_info>
    <org_study_id>AOM-01-076</org_study_id>
    <secondary_id>PHRC National 2001</secondary_id>
    <nct_id>NCT00487630</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease</brief_title>
  <acronym>HEART</acronym>
  <official_title>A Multicenter, Phase 4, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Recombinant Alpha-Galactosidase A (Agalsidase Beta, FABRAZYME) in Heterozygous Females for Fabry Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fabry disease (OMIM 301500) is an X-linked inborn error of sphingolipid metabolism resulting
      from the deficiency of the lysosomal enzyme alpha-galactosidase A. Heterozygous females for
      Fabry disease may be symptomatic with cardiac, renal or cerebrovascular involvement.
      Clearance of Gb3 and stabilization of renal function has been demonstrated in male patients
      treated with agalsidase beta (FABRAZYME). In contrast, no randomized, controlled study of the
      efficacy of recombinant alpha-galactosidase A has been reported in heterozygotes for Fabry
      disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to evaluate cardiac left ventricular mass (measured with
      echocardiography by unique investigator) in females over 15 years of age affected with Fabry
      disease receiving 70 mg of agalsidase beta every other week, as compared with an untreated
      controlled group matched for gender and age.

      The secondary objectives include evaluation of :

        -  left ventricular posterior wall thickness (echocardiography)

        -  interventricular septum thickness (echocardiography)

        -  tissue doppler imaging (myocardial function)

        -  EKG

        -  creatinaemia

        -  serum cystatin C level

        -  urinary protein/creatinine ratio

        -  microalbuminuria

        -  Gb3 urinary levels

      Evaluation of tolerance and safety with :

        -  Home therapy infusions follow up

        -  Vitals

        -  Physical examination

        -  Adverse events

        -  Antibodies levels
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2005</start_date>
  <completion_date type="Anticipated">June 2009</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular mass</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Posterior wall thickness, interventricular thickness, ECG, creatinaemia, urinary protein / creatinine ratio, microalbuminuria, urinary Gb3 level</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Fabry Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant alpha-galactosidase A</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients over 15 years with clinical and biological evidence of Fabry disease
             (GLA gene mutation detected)

        Exclusion Criteria:

          -  Pregnancy

          -  Allergy to agalsidase beta

          -  Congestive heart failure

          -  Creatinaemia &gt; 135 µmol/l

          -  Medical history of stroke during the last year

          -  Medical history of more than 2 transient ischemic attack

          -  Blood pressure &gt; 160/95

          -  Modification in medications treating for blood pressure during the last 3 months
             before enrollment

          -  Complete absence of clinical or biological symptoms

          -  Weight &gt; 87 kg or &lt; 35 kg
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique P GERMAIN, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de reference de la maladie de Fabry et des maladies hereditaires du tissu conjonctif. Assistance Publique Hopitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique P GERMAIN, MD, PhD</last_name>
    <phone>+33156092306</phone>
    <email>dominique.germain@egp.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karelle BENISTAN, MD</last_name>
    <phone>+33156092802</phone>
    <email>karelle.benistan@egp.aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de reference de la maladie de Fabry et des maladies hereditaires du tissu conjonctif. Assistance Publique - Hôpitaux de Paris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dominique P GERMAIN, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karelle BENISTAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Albert A HAGEGE, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles CHATELLIER, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2007</study_first_submitted>
  <study_first_submitted_qc>June 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2007</study_first_posted>
  <last_update_submitted>June 15, 2007</last_update_submitted>
  <last_update_submitted_qc>June 15, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2007</last_update_posted>
  <keyword>Heterozygous females</keyword>
  <keyword>Cardiomyopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

